Reaction
Metapneumovirus Infection reporting signals
As of the last recalculation, Metapneumovirus Infection appears in 749 FAERS reports alongside 34 co-occurring drug terms. The strongest observed disproportionality signal is PALIVIZUMAB (PRR 70.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Palivizumab | 37 | 70.4 | 70.5 |
| Busulfan | 22 | 40.0 | 40.1 |
| Melphalan | 29 | 36.8 | 36.9 |
| Melphalan Hydrochloride | 31 | 35.8 | 35.8 |
| Thiotepa | 12 | 35.5 | 35.5 |
| Selexipag | 30 | 33.6 | 33.6 |
| Oseltamivir | 8 | 28.2 | 28.2 |
| Ganciclovir | 10 | 27.5 | 27.5 |
| Sirolimus | 13 | 27.3 | 27.3 |
| Ganciclovir Sodium | 10 | 26.6 | 26.6 |
| Micafungin Sodium | 8 | 26.5 | 26.5 |
| Clobazam | 21 | 24.6 | 24.6 |
| Crizotinib | 11 | 24.4 | 24.4 |
| Anti-Thymocyte Globulin (Rabbit) | 7 | 24.3 | 24.4 |
| Mesna Injection | 7 | 23.8 | 23.8 |
| Fludarabine Phosphate | 32 | 23.6 | 23.6 |
| Mesna | 7 | 23.3 | 23.3 |
| Valganciclovir Hydrochloride Powder, | 10 | 23.1 | 23.1 |
| Mercaptopurine | 14 | 22.8 | 22.9 |
| Valganciclovir | 15 | 22.5 | 22.6 |
| Valganciclovir Hydrochloride | 15 | 22.5 | 22.6 |
| Blinatumomab | 7 | 18.8 | 18.8 |
| Posaconazole | 9 | 15.6 | 15.6 |
| Bortezomib | 43 | 14.1 | 14.1 |
| Sevoflurane | 4 | 13.4 | 13.4 |
| Temozolomide | 10 | 13.4 | 13.4 |
| Vigabatrin | 6 | 11.5 | 11.5 |
| Pegaspargase | 5 | 11.4 | 11.4 |
| Bosentan | 20 | 11.3 | 11.3 |
| Cannabidiol | 9 | 10.8 | 10.8 |
| Eltrombopag Olamine | 8 | 9.7 | 9.7 |
| Ixazomib | 9 | 8.8 | 8.8 |
| Ambrisentan | 33 | 7.6 | 7.6 |
| Pomalidomide | 21 | 5.8 | 5.8 |